ProfileGDS5678 / 1438044_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 41% 35% 36% 34% 34% 36% 35% 36% 34% 36% 36% 34% 36% 36% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9786741
GSM967853U87-EV human glioblastoma xenograft - Control 22.8036935
GSM967854U87-EV human glioblastoma xenograft - Control 32.8259836
GSM967855U87-EV human glioblastoma xenograft - Control 42.7170134
GSM967856U87-EV human glioblastoma xenograft - Control 52.7305434
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9117936
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8434735
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8197536
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7539134
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8007536
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8091336
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.740834
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8181236
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8163436